Research Analysts Set Expectations for CLRB Q2 Earnings
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) – Equities research analysts at Roth Capital lifted their Q2 2025 earnings per share estimates for Cellectar Biosciences in a research report issued on Tuesday, May 13th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter, […]
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) – Equities research analysts at Roth Capital lifted their Q2 2025 earnings per share estimates for Cellectar Biosciences in a research report issued on Tuesday, May 13th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter, […]
